- Home
- RNXT vs IPSC Comparison
RNXT vs IPSC Comparison
Compare RNXT & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- IPSC
- Stock Information
- Founded
- RNXT 2012
- IPSC 2019
- Country
- RNXT United States
- IPSC United States
- Employees
- RNXT N/A
- IPSC N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- RNXT Health Care
- IPSC Health Care
- Exchange
- RNXT Nasdaq
- IPSC Nasdaq
- Market Cap
- RNXT 43.2M
- IPSC 43.2M
- IPO Year
- RNXT 2021
- IPSC 2021
- Fundamental
- Price
- RNXT $1.11
- IPSC $0.59
- Analyst Decision
- RNXT Strong Buy
- IPSC Strong Buy
- Analyst Count
- RNXT 2
- IPSC 5
- Target Price
- RNXT $7.50
- IPSC $3.33
- AVG Volume (30 Days)
- RNXT 851.9K
- IPSC 535.0K
- Earning Date
- RNXT 11-12-2025
- IPSC 11-04-2025
- Dividend Yield
- RNXT N/A
- IPSC N/A
- EPS Growth
- RNXT N/A
- IPSC N/A
- EPS
- RNXT N/A
- IPSC N/A
- Revenue
- RNXT $662,000.00
- IPSC $114,128,000.00
- Revenue This Year
- RNXT $2,895.35
- IPSC $1,589.94
- Revenue Next Year
- RNXT $313.04
- IPSC N/A
- P/E Ratio
- RNXT N/A
- IPSC N/A
- Revenue Growth
- RNXT N/A
- IPSC 5491.77
- 52 Week Low
- RNXT $0.75
- IPSC $0.34
- 52 Week High
- RNXT $1.69
- IPSC $1.83
- Technical
- Relative Strength Index (RSI)
- RNXT 42.40
- IPSC 71.90
- Support Level
- RNXT $1.24
- IPSC $0.48
- Resistance Level
- RNXT $1.42
- IPSC $0.51
- Average True Range (ATR)
- RNXT 0.10
- IPSC 0.03
- MACD
- RNXT -0.01
- IPSC 0.01
- Stochastic Oscillator
- RNXT 11.08
- IPSC 97.74
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.